OcuTerra Therapeutics is evaluating strategic alternatives after the phase 2 DR:EAM trial failed to meet its primary efficacy endpoint, according to a press release.
The trial investigated the use of nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy.
Trial data showed that nesvategrast was safe and well tolerated. However, it failed to meet the primary efficacy endpoint of the percentage of patients with a two-step or greater improvement in Diabetic Retinopathy Severity Scale (DRSS), as well as the secondary endpoint of impact on the progression of disease as (Read more...)